Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Ascendis Pharma price target raised to $154 from $149 at Credit Suisse » 08:24
05/20/20
05/20
08:24
05/20/20
08:24
ASND

Ascendis Pharma

$142.12 /

+1.3 (+0.92%)

Credit Suisse analyst…

Credit Suisse analyst Tiago Fauth raised the firm's price target on Ascendis Pharma to $154 from $149 and keeps an Outperform rating on the shares. The analyst notes that the company has reiterated timelines for a TransCon hGH BLA submission in Q2, and guided for a Q3 MAA submission, a quarter earlier than originally expected, setting up a launch in pediatric GH deficiency in 2021.

ShowHide Related Items >><<
ASND Ascendis Pharma
$142.12 /

+1.3 (+0.92%)

ASND Ascendis Pharma
$142.12 /

+1.3 (+0.92%)

05/20/20 Oppenheimer
Ascendis Pharma price target lowered to $208 from $219 at Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
04/20/20 Morgan Stanley
Ascendis' TransCon PTH 'could be a game changer,' says Morgan Stanley
04/20/20 JPMorgan
Ascendis Pharma price target raised to $150 from $145 at JPMorgan
ASND Ascendis Pharma
$142.12 /

+1.3 (+0.92%)

ASND Ascendis Pharma
$142.12 /

+1.3 (+0.92%)

Recommendations
Ascendis Pharma price target lowered to $208 from $219 at Oppenheimer » 07:47
05/20/20
05/20
07:47
05/20/20
07:47
ASND

Ascendis Pharma

$142.12 /

+1.3 (+0.92%)

Oppenheimer analyst…

Oppenheimer analyst Leland Gershell lowered the firm's price target on Ascendis Pharma to $208 from $219 on modestly higher R&D expense projections. The analyst keeps an Outperform rating on the shares.

ShowHide Related Items >><<
ASND Ascendis Pharma
$142.12 /

+1.3 (+0.92%)

ASND Ascendis Pharma
$142.12 /

+1.3 (+0.92%)

04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
04/20/20 Morgan Stanley
Ascendis' TransCon PTH 'could be a game changer,' says Morgan Stanley
04/20/20 JPMorgan
Ascendis Pharma price target raised to $150 from $145 at JPMorgan
04/20/20 Oppenheimer
Ascendis Pharma price target raised to $219 from $199 at Oppenheimer
ASND Ascendis Pharma
$142.12 /

+1.3 (+0.92%)

ASND Ascendis Pharma
$142.12 /

+1.3 (+0.92%)

Over a week ago
Earnings
Ascendis Pharma reports Q1 EPS (EUR 1.32), consensus (EUR 1.30) » 16:13
05/19/20
05/19
16:13
05/19/20
16:13
ASND

Ascendis Pharma

$142.51 /

+1.69 (+1.20%)

Reports Q1 revenue EUR…

Reports Q1 revenue EUR 2.23M, consensus EUR 1.9M. As of March 31, Ascendis Pharma had cash and cash equivalents of EUR 534.4M compared to EUR 598.1M as of December 31, 2019.

ShowHide Related Items >><<
ASND Ascendis Pharma
$142.51 /

+1.69 (+1.20%)

ASND Ascendis Pharma
$142.51 /

+1.69 (+1.20%)

04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
04/20/20 Morgan Stanley
Ascendis' TransCon PTH 'could be a game changer,' says Morgan Stanley
04/20/20 JPMorgan
Ascendis Pharma price target raised to $150 from $145 at JPMorgan
04/20/20 Oppenheimer
Ascendis Pharma price target raised to $219 from $199 at Oppenheimer
ASND Ascendis Pharma
$142.51 /

+1.69 (+1.20%)

Hot Stocks
Ascendis Pharma to appoint Jesper Hoiland as global CCO » 09:14
05/11/20
05/11
09:14
05/11/20
09:14
ASND

Ascendis Pharma

$137.39 /

-4.305 (-3.04%)

, RDUS

Radius Health

$14.57 /

-0.46 (-3.06%)

Ascendis Pharma (ASND)…

Ascendis Pharma (ASND) announced that the company will appoint Jesper Hoiland as Global Chief Commercial Officer upon completion of his transition from Radius Health (RDUS). Mr. Hoiland most recently served as President and Chief Executive Officer of Radius Health until May 2020.

ShowHide Related Items >><<
ASND Ascendis Pharma
$137.39 /

-4.305 (-3.04%)

04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
04/20/20 Morgan Stanley
Ascendis' TransCon PTH 'could be a game changer,' says Morgan Stanley
04/20/20 JPMorgan
Ascendis Pharma price target raised to $150 from $145 at JPMorgan
04/20/20 Oppenheimer
Ascendis Pharma price target raised to $219 from $199 at Oppenheimer
RDUS Radius Health
$14.57 /

-0.46 (-3.06%)

04/24/20
Fly Intel: Top five analyst initiations
04/23/20 Stifel
Radius Health initiated with a Hold at Stifel
04/23/20 Stifel
Radius Health initiated with a Hold at Stifel
11/06/19 SVB Leerink
Radius Health price target lowered to $35 from $49 at SVB Leerink
Over a month ago
Recommendations
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink » 09:22
04/20/20
04/20
09:22
04/20/20
09:22
ASND

Ascendis Pharma

$128.73 /

+0.46 (+0.36%)

, TAK

Takeda Pharmaceutical

$16.81 /

+0.285 (+1.73%)

SVB Leerink analyst…

SVB Leerink analyst Joseph Schwartz raised the firm's price target on Ascendis Pharma (ASND) to $170 from $152 and keeps an Outperform rating on the shares. The analyst notes that the company reported positive Phase 2 PaTH Forward data for TransCon PTH that falls under his base case scenario. Although the timing of the regulatory path forward remains uncertain in light of COVID-19, Schwartz believes that an expedited regulatory path is in Ascendis' favor due to a potential pent up demand from Takeda's (TAK) Natpara being pulled from the market and the FDA's draft guidance that outlines more liberal requirements for "evidence of effectiveness."

ShowHide Related Items >><<
ASND Ascendis Pharma
$128.73 /

+0.46 (+0.36%)

04/20/20 Morgan Stanley
Ascendis' TransCon PTH 'could be a game changer,' says Morgan Stanley
04/20/20 JPMorgan
Ascendis Pharma price target raised to $150 from $145 at JPMorgan
04/20/20 Oppenheimer
Ascendis Pharma price target raised to $219 from $199 at Oppenheimer
04/20/20 Canaccord
Ascendis Pharma price target raised to $170 from $166 at Canaccord
TAK Takeda Pharmaceutical
$16.81 /

+0.285 (+1.73%)

03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
03/25/20 Stifel
Molecular Templates initiated with a Buy at Stifel
02/25/20 Stifel
Iovance among 'more interesting' cell therapy takeout candidates, says Stifel
02/12/20 Wells Fargo
Fate Therapeutics price target raised to $34 from $24 at Wells Fargo
Recommendations
Ascendis' TransCon PTH 'could be a game changer,' says Morgan Stanley » 09:01
04/20/20
04/20
09:01
04/20/20
09:01
ASND

Ascendis Pharma

$128.73 /

+0.46 (+0.36%)

After Ascendis Pharma…

After Ascendis Pharma released top line data from the Phase 2 PaTH Forward trial examining TransCon PTH for the treatment of hyperparathyroidism, Morgan Stanley analyst David Lebowitz said the drug "clearly" is a big step ahead of Natpara and "could be a game changer" for patients in suffering from this condition. He finds it significant that so many patients in the trial were removed from standard of care with no substantive safety issues, added Lebowitz, who keeps an Overweight rating on Ascendis shares with a $180 price target.

ShowHide Related Items >><<
ASND Ascendis Pharma
$128.73 /

+0.46 (+0.36%)

04/20/20 JPMorgan
Ascendis Pharma price target raised to $150 from $145 at JPMorgan
04/20/20 Oppenheimer
Ascendis Pharma price target raised to $219 from $199 at Oppenheimer
04/20/20 Canaccord
Ascendis Pharma price target raised to $170 from $166 at Canaccord
04/20/20 Credit Suisse
Ascendis Pharma price target raised to $149 from $139 at Credit Suisse
Recommendations
Ascendis Pharma price target raised to $150 from $145 at JPMorgan » 08:44
04/20/20
04/20
08:44
04/20/20
08:44
ASND

Ascendis Pharma

$128.73 /

+0.46 (+0.36%)

JPMorgan analyst Jessica…

JPMorgan analyst Jessica Fye raised the firm's price target on Ascendis Pharma to $150 from $145 and reiterates an Overweight rating on the shares. The company's topline results support TransCon PTH as a true replacement therapy, Fye tells investors in a research note.

ShowHide Related Items >><<
ASND Ascendis Pharma
$128.73 /

+0.46 (+0.36%)

04/20/20 Oppenheimer
Ascendis Pharma price target raised to $219 from $199 at Oppenheimer
04/20/20 Canaccord
Ascendis Pharma price target raised to $170 from $166 at Canaccord
04/20/20 Credit Suisse
Ascendis Pharma price target raised to $149 from $139 at Credit Suisse
04/20/20 Cantor Fitzgerald
Ascendis Pharma price target raised to $201 from $185 at Cantor Fitzgerald
Recommendations
Ascendis Pharma price target raised to $219 from $199 at Oppenheimer » 08:36
04/20/20
04/20
08:36
04/20/20
08:36
ASND

Ascendis Pharma

$128.73 /

+0.46 (+0.36%)

Oppenheimer analyst…

Oppenheimer analyst Leland Gershell raised the firm's price target on Ascendis Pharma to $219 from $199 on increased likelihood of success for TransCon PTH, and as he views further platform validation as derisking earlier pipeline programs. The analyst keeps an Outperform rating on the shares.

ShowHide Related Items >><<
ASND Ascendis Pharma
$128.73 /

+0.46 (+0.36%)

04/20/20 Canaccord
Ascendis Pharma price target raised to $170 from $166 at Canaccord
04/20/20 Credit Suisse
Ascendis Pharma price target raised to $149 from $139 at Credit Suisse
04/20/20 Cantor Fitzgerald
Ascendis Pharma price target raised to $201 from $185 at Cantor Fitzgerald
04/20/20 Stifel
Ascendis Pharma price target raised to $171 from $146 at Stifel
Recommendations
Ascendis Pharma price target raised to $170 from $166 at Canaccord » 07:46
04/20/20
04/20
07:46
04/20/20
07:46
ASND

Ascendis Pharma

$128.73 /

+0.46 (+0.36%)

Canaccord analyst…

Canaccord analyst Michelle Gilson raised the firm's price target on Ascendis Pharma to $170 from $166 and keeps a Buy rating on the shares. The analyst raised her price target following its report of top line data from a Phase 2 study of TransCon PTH in hypoparathyroidism which provided a proof of concept as a disease modifying therapeutic in hypothyroidism. The results validated the drug as a treatment for hypothryroidism, not an adjunct treatment.

ShowHide Related Items >><<
ASND Ascendis Pharma
$128.73 /

+0.46 (+0.36%)

04/20/20 Credit Suisse
Ascendis Pharma price target raised to $149 from $139 at Credit Suisse
04/20/20 Cantor Fitzgerald
Ascendis Pharma price target raised to $201 from $185 at Cantor Fitzgerald
04/20/20 Stifel
Ascendis Pharma price target raised to $171 from $146 at Stifel
03/31/20 Canaccord
Ascendis Pharma price target raised to $166 from $144 at Canaccord
Recommendations
Ascendis Pharma price target raised to $149 from $139 at Credit Suisse » 07:42
04/20/20
04/20
07:42
04/20/20
07:42
ASND

Ascendis Pharma

$128.73 /

+0.46 (+0.36%)

Credit Suisse analyst…

Credit Suisse analyst Tiago Fauth raised the firm's price target on Ascendis Pharma to $149 from $139 and keeps an Outperform rating on the shares. The analyst notes that the company reported data from its Phase 2 TransCon PTH trial in subjects with hypoparathyroidism, demonstrating that all participants in the 21 microg/day arm were able to eliminate SoC versus only 15% of subjects on placebo. Importantly, there were no TEAEs leading to discontinuation of the drug, and safety results were overall in-line with expected PTH pharmacology and relatively benign, he adds.

ShowHide Related Items >><<
ASND Ascendis Pharma
$128.73 /

+0.46 (+0.36%)

04/20/20 Cantor Fitzgerald
Ascendis Pharma price target raised to $201 from $185 at Cantor Fitzgerald
04/20/20 Stifel
Ascendis Pharma price target raised to $171 from $146 at Stifel
03/31/20 Canaccord
Ascendis Pharma price target raised to $166 from $144 at Canaccord
03/19/20 Oppenheimer
Oppenheimer starts injection 'innovator' Ascendis Pharma at Outperform

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.